malaysia onclogy
   
 
malaysiaoncology.org | Malaysian Oncological Society
home home home home
    search
Terminology
Misconceptions
Diagnosis
Treatments
Common Cancers
Informed Decision
Featured Expert
Palliative Care
Specialist Centres
Upcoming Events
FAQ
Ask Question
Web Resources
In the News
Supportive Info
Clinical Trials
Photo Gallery
Cancer Survivorship
President's Message
Living with Cancer
Toolbox
Home
Feedback
   
 

Main sponsors:
AstraZeneca Sdn Bhd
Novartis Corporation (Malaysia) Sdn. Bhd
Roche (Malaysia) Sdn. Bhd.
Sanofi-Aventis Malaysia Sdn Bhd
GlaxoSmithKline Pharmaceutical Sdn Bhd
Pfizer Malaysia Sdn Bhd
  arrow In the News

    Food for thought
26-01-2009
It amazes me to think how old I am. I grew up in a time when notions like “wind” (angin, hong, foong to use the vernacular) and “heatiness” (panas, yeet hei) were all pervasive.
» Read more...
 

    Plant foods and cancer prevention
22-01-2009
Eat more of a variety of vegetables and fruits, cereals and pulses such as beans to help prvent cancer.
» Read more...
 

    A better future
22-01-2009
Science is still the best bet for a future that will hopefully see solutions to problems that bedevil us.
» Read more...
 

    Oh me throat
15-01-2009
You can literally lose your voice, and much more, if throat cancer. strikes
» Read more...
 

    Just quit smoking
15-01-2009
Tobacco use is a major cause of premature and preventable death in the world.
» Read more...
 

    Zoledronic acid reduces disseminated tumor cells in the bone marrow of patients with primary breast cancer
12-01-2009
Disseminated tumor cells (DTCs) in the bone marrow have been the subject of numerous clinical trials evaluating their impact on prognosis.
» Read more...
 

    ZO-FAST update: Zoledronic acid prevents AI mediated bone loss and improves DFS
12-01-2009
Aromatase inhibitors (AIs) including letrozole, anastrozole, and exemestane have increased the adjuvant therapeutic options for postmenopausal patients with hormone receptor-positive breast cancer.
» Read more...
 

    Exploratory analyses of the phase III AZURE trial: The addition of zoledronic acid to neoadjuvant chemotherapy improves pathological response
7-01-2009
A retrospective exploratory analysis of the phase III AZURE trial (n=3,360) was conducted in women with stage II/III breast cancer received neoadjuvant chemotherapy plus zoledronic acid (4mg IV).
» Read more...
 


 
   
 

terms of use | sponsors | credits

Copyright © malaysiaoncology.org 2004 - 2010   All rights reserved
designed & maintained: mobition